17 October 2024
Futura Medical
plc
("Futura", "the Group" or the "Company")
Clinical
trial data presented at SMSNA
Futura Medical plc (AIM: FUM), the
consumer healthcare company behind Eroxon®, that
specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces
that three abstracts on MED3000 are being presented at the Sexual
Medicine Society of North America (SMSNA) at their annual
conference in Scottsdale, Arizona on 17th to
20th October. The SMSNA
promotes, encourages, and supports the highest standards of
practice, research, education, and ethics in the study of human
sexual function and dysfunction.
The abstracts detail the results of
clinical trials, showing the positive impact of MED3000 on Erectile
Dysfunction (ED) but also self-esteem and relationships in men with
ED and sexual encounter profiles for men and their
partners.
The importance of the presentation
of these abstracts is to educate and improve awareness amongst key
opinion leaders and other healthcare practitioners about the
benefits of MED3000 (now available through the USA under the brand
name Eroxon®) as a clinical proven treatment for
ED.
Details of the of the abstracts,
methods and results can be found at: https://www.smsna.org/annual2024/program
|
Abstract 1
|
Topical Administration of MED3000
Gel Significantly Improves Self-esteem and Relationships in Men
with Erectile Dysfunction: Results from Two Clinical
Trials
|
|
Abstract 2
|
Topical Administration of MED3000
Gel Significantly Improves Erectile Function in Men with Mild,
Moderate, or Severe Erectile Dysfunction: Results from Two
Multicenter Clinical Trials
|
|
Abstract 3
|
Topical Administration of MED3000
Gel Significantly Improves All Aspects of the Sexual Encounter
Profile for Both Men and Their Partners
|
The abstracts are presented to the
audience and then all abstracts presented at the meeting will be
published in a supplement of the Journal of Sexual
Medicine.
Contacts:
|
Futura Medical
plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl, Will Goode,
Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma
Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally across
all adult age brackets, with approximately half of all men over 40
experiencing ED and 25% of all new diagnoses being in men under
40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.